
KTTA Stock Forecast & Price Target
KTTA Analyst Ratings
Bulls say
Pasithea Therapeutics is supported by early clinical evidence showing PAS-004 produced consistent cNF shrinkage across all 15 evaluable participants, with a median best reduction of 41% and 87% of patients achieving more than 20% reduction, while 18 PN participants also showed volumetric decreases. The profile is further strengthened by de-risking regulatory and safety signals, including FDA clearance to proceed with a randomized Phase 2 in about 200 adults, no treatment-related serious adverse events or discontinuations, and only 33% rash at the Phase 2 doses, all Grade 1. Its outlook is also bolstered by a large underserved NF1 market, a potential priority review voucher, and management’s conservative valuation that still assigns meaningful upside from PAS-004 while leaving additional solid-tumor opportunity unmodeled.
Bears say
Pasithea Therapeutics is a speculative biotechnology company whose outlook is weighed down by a high risk of failed or inconclusive clinical trials, especially given the lack of a validated regulatory endpoint for cNF. Its development pipeline remains exposed to funding shortfalls and the need for dilutive capital raises, which could weaken shareholder value before any meaningful clinical or regulatory progress is achieved. Competition from approved and emerging MEK inhibitor therapies further raises the bar for PAS-004 and the broader CNS and oncology pipeline, making successful differentiation and commercialization uncertain.
This aggregate rating is based on analysts' research of Pasithea Therapeutics Corp and is not a guaranteed prediction by Public.com or investment advice.
KTTA Analyst Forecast & Price Prediction
Start investing in KTTA
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Pasithea Therapeutics Corp (KTTA) Forecast
KTTA Analyst Forecast & Price Prediction
Start investing in KTTA
Order type
Buy in
Order amount
Est. shares
0 shares